Our mission is to help people see more clearly and improve their quality of life.

Our technology is clinically proven to improve vision across a variety of vision conditions and is FDA-cleared for amblyopia over age 9. RevitalVision enhances the brain's visual processing, enabling significant vision improvements beyond standard eye care, truly making a difference

Meet the Team

Yair Yahav

Founder & CEO

Yogev Shamay

Co-founder & CTO

Yuval Ron-Ruhama

COO

Charles Morris

General Manager –N. America

Yonina Thee

Clinical Specialist

Inbal Sasson

Clinical Research Manager

Shlomo Abramson

Clinical Service Manager

Rona Erlich

Marketing Director

Board

Yariv Baron

Director

Dr. Shulamit Hadi

Director

Alon Reshef

Director & Shareholder

Simon Kan

Director

Advisory Board

Amir Belson, M.D.

Advisory Board

Prof. Richard W. Hertle (MD)

Scientific & Clinical Advisor

Prof. Ramesh
 Kekunnaya (MD)

Scientific & Clinical Advisor

Dr. Sarah Maling (MD)

Advisory Board

Mike Turner

Advisory Board

Prof. Yair Morad (MD)

Scientific & Clinical Advisor

Latest News and Events

21-24 April 2021

REVITALVISION will participate at the upcoming 41st ESA (EUROPEAN STRABISMOLOGICAL ASSOCIATION)

Meeting in PARIS 21th /24th April 2021

Link to article

2020

A New Adult Amblyopia study presented at AIOS 2020 (All India Ophthalmology Society)

meeting 2020 confirming again the efficacy of RevitalVision in improving vision in adult amblyopia

Download ppt

7 October

REVITALVISION will participate at the upcoming AAOPT (AMERICAN ACADEMY of OOPTOMETRY)

Meeting in Nashville, TN, USA 7-10 October

Link to article

2020

Tel Aviv Medical Center is recruiting Age related Macular Degeneration patients for a REVITALVISION clinical study

A Proof-of-Concept, Prospective, Open label, Randomized Clinical Study Evaluating RevitalVision® Therapy for Improving Best Corrected Visual Acuity (BCVA) and Contrast Sensitivity Function (CSF) in Patients Suffering from stabler Age related Macular Degeneration (AMD)

« 1 … 5 6 7